We have used biochemical, molecular & cell biology and in vivo models to screen, identify and characterize suitable candidate biopharmaceuticals targeting major Central Nervous System disorders with unmet medical need. Our lead product under development is Leptin, an adipocyte hormone, thought to control energy homeostasis, now known to have pleiotropic activities. We are renaming to MEMTIN.
Epidemiological data suggest that Leptin can be administered as a replacement therapy to mild cognitively-impaired /at risk and Alzheimerâs disease (AD) patients, often characterized by Leptin-deficiency. We have accumulated compelling data in support of Leptinâs disease-modifying potential and its cognitive enhancing properties. We are currently manufacturing a cGMP product and are preparing for human trials.
In addition, we have identified an abnormal protein-protein interaction in a subset of familial cases of early onset AD. This abnormal interaction between mutated Presenilin with CLIP-170 is linked to higher Ab levels, a small peptide known to be integral to disease pathology. Disruption of this interaction in vitro can lower Ab production and we plan to test this further.
Source
